ProfileGDS5678 / 1428376_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 6% 8% 6% 5% 6% 6% 6% 5% 6% 6% 5% 5% 6% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.124786
GSM967853U87-EV human glioblastoma xenograft - Control 22.105516
GSM967854U87-EV human glioblastoma xenograft - Control 32.19678
GSM967855U87-EV human glioblastoma xenograft - Control 42.055746
GSM967856U87-EV human glioblastoma xenograft - Control 52.049875
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.173556
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.110736
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.081416
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.062965
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.09326
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.090686
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.065845
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.083625
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.093276